Fresenius Se ( (FSNUY) ) has released its Q4 earnings. Here is a breakdown of the information Fresenius Se presented to its investors.
Fresenius SE & Co. KGaA is a global healthcare company based in Bad Homburg, Germany, known for its operations in the healthcare sector through its subsidiaries Fresenius Kabi and Fresenius Helios, and its investment in Fresenius Medical Care. The company focuses on providing healthcare products and services, including biopharmaceuticals, clinical nutrition, and hospital operations.
In its latest earnings report for the fiscal year 2024, Fresenius reported a successful year with strong financial performance. The company achieved an 8% organic revenue growth, reaching €21.5 billion, and a 10% increase in EBIT to €2.5 billion. Net income grew by 13% to €1,461 million, and earnings per share rose to €2.59. The company also reported significant productivity savings and a reduction in its net debt/EBITDA ratio to 3.0x.
Key highlights include Fresenius Kabi’s impressive organic revenue growth of 10% and an EBIT margin expansion to 15.7%, driven by strong performances in its MedTech, Nutrition, and Biopharma segments. Fresenius Helios also contributed with a 6% organic revenue growth, although its EBIT was impacted by the end of energy relief payments in Germany. Despite this, Helios Spain showed strong profitability with a 15.8% EBIT margin.
Looking ahead, Fresenius aims to continue its growth trajectory with expectations of 4% to 6% revenue growth and 3% to 7% EBIT growth in 2025. The company plans to focus on further debt reduction, higher margins for Kabi, and operational improvements at Helios. Fresenius is committed to enhancing shareholder value through a new dividend policy and strategic flexibility.
Overall, Fresenius SE & Co. KGaA is poised for continued success as it enters the next phase of its #FutureFresenius initiative, focusing on innovation and performance to drive future growth.